trelagliptin trade name zafatek pharmaceutical drug used treatment type diabetes diabetes highly selective dipeptidyl inhibitor typically used add treatment first line treatment metformin achieving expected glycemic goals though approved use first line treatment metformin inhibitors activate tcells commonly known tcell activation antigens specifically chemically fluorinated derivative alogliptin formulated salt trelagliptin succinate approved use japan march takeda company developed trelagliptin chose get approval drug us licensing rights takeda purchased furiex pharmaceuticals inhibitors included clause specific development drug us clause required services done phase ii phase iii clinical studies us eu purchased takeda chose cease development drug us eu high costs quoted furiex gliptins market since gliptins currently registered drugs gliptins emerging market thus developed increasing rate currently two gliptins advanced stages development expected market coming gliptins thought cardiovascular protective abilities though extent effects still also studied ability class drugs promoting bcell similar drugs class trelagliptin administered daily trelagliptin administered alogliptin nesina major inhibitor market also owned takeda administered daily dosing per week advantageous reduction frequency required dosing known increase patient recent metaanalysis published dutta et al highlighted good glycaemic efficacy safety molecule compared peer inhibitors taken daily like alogliptin sitagliptin linagliptin teneligliptin anagliptin vildagliptin advantage reducing monthly pill count bangladesh marketed trade name wedica httpsenwikipediaorgwikitrelagliptin